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ABSTRACT 
Prosthetic joint infection (PJI) is a devastating complication associated with total joint arthroplasty 
that results in high cost and patient morbidity. There are approximately 50,000 PJIs per year in 
the US, imposing a burden of about $5 billion on the healthcare system. PJI is especially difficult 
to treat because of the presence of bacteria in biofilm, often highly tolerant to antimicrobials. 
Treatment of PJI requires surgical debridement of infected tissues, and local, sustained delivery 
of antimicrobials at high concentrations to eradicate residual biofilm bacteria. However, the 
antimicrobial concentrations required to eradicate biofilm bacteria grown in vivo or on tissue 
surfaces have not been measured. In this study, an experimental rabbit femur infection model 
was established by introducing a variety of pathogens representative of those found in PJIs 
[Staphylococcus Aureus (ATCC 49230, ATCC BAA-1556, ATCC BAA-1680), Staphylococcus 
Epidermidis (ATCC 35984, ATCC 12228), Enterococcus Faecalis (ATCC 29212), Pseudomonas 
Aeruginosa (ATCC 27853), Escherichia Coli (ATCC 25922)]. Biofilms of the same pathogens 
were grown in vitro on biologic surfaces (bone and muscle). The ex vivo and in vitro tissue 
minimum biofilm eradication concentration (MBEC; the level required to eradicate biofilm 
bacteria) and minimum inhibitory concentration (MIC; the level required to inhibit planktonic, non-
biofilm bacteria) were measured using microbiological susceptibility assays against tobramycin 
(TOB) and vancomycin (VANC) alone or in 1:1 weight combination of both (TOB+VANC) over 
three exposure durations (6 hour, 24 hour, 72 hour). MBECs for all treatment combinations 
(pathogen, antimicrobial used, exposure time, and tissue) were compared against the 
corresponding MIC values to compare the relative susceptibility increase due to biofilm formation. 
Our data showed median in vitro MBEC to be 100-1000 times greater than the median MIC 
demonstrating the administration of local antimicrobial doses at MIC level would not kill the 
persisting bacteria in biofilm. Also, administering dual agent (TOB+VANC) showed median MBEC 
values to be comparable or lower than the single agents (TOB or VANC)  
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CHAPTER 1 – INTRODUCTION 
1.1 Prosthetic Joint Infection (PJI) 
Prosthetic joint infection is usually caused by bacteria adhering to an implant and adjacent 
biological surfaces and formation of an exopolysaccharide matrix (biofilm). It leads to the 
complete destruction of the joint with potential to spread to other sites causing life-threatening 
conditions if not diagnosed and treated properly. With the presence of a prosthetic device, the 
probability of infection in the joint rises. In the United States alone, more than one million 
arthroplasties are conducted each year and it is estimated to rise to four million by 2030.1 With 
more than 50,000 PJIs each year in the United States,2-3 and treatment of each case costing over 
$100,000,4-6 PJIs impose a burden of more than $5 billion on the healthcare system.  
In implant-related infections, the biofilm matrix can establish and enhance tolerance to 
antimicrobials by limiting the diffusion of antimicrobials to the bacterial cells or by producing 
enzymes to counteract the antimicrobial effects.7-11 The most important characteristic of bacterial 
biofilms is that they host a subpopulation of bacteria called persister cells. Persister cells are 
dormant, non-dividing, and often multi-drug resistant.12-13 Consequently, compared to their 
planktonic counterparts, bacteria in biofilms exhibit increased tolerance to antimicrobials. 
Adequate treatment of a biofilm-based infection requires a combination of surgical removal of the 
vast majority (ideally all) of the infection, and multi-day antimicrobial exposure levels capable of 
killing persister cells as the host response is often not effective.12-13 The antimicrobial levels 
should be sufficiently maintained to eradicate any remaining bacteria. The minimum biofilm 
eradication concentration (MBEC), which is the antimicrobial concentration required to sterilize a 
biofilm, is reported to be 10 – 1000x greater14-17 than the minimum inhibitory concentration (MIC), 
which is the concentration of antimicrobials required to inhibit the overnight growth of planktonic, 
free floating bacteria.18-23 Unlike the MIC for a typical antimicrobial-bacterium pair (which is on the 
order of 0.5-8 µg/mL), MBEC values are often much higher than concentration of antimicrobials 
that can be provided safely by systemic administration. 
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The figure below represents typical barriers and mechanisms involved in the increased tolerance 
of biofilms against antimicrobial agents. 
 
Fig 1.1 Potential mechanisms of Biofilm Tolerance24  
(1) Failure of antimicrobial agents to penetrate the biofilm surface layers; (2) Antimicrobial agents 
may be trapped and destroyed by enzymes in the biofilm matrix; (3) Antimicrobial agents may not 
be active against non-growing persister cells;. (4) Possible expression of biofilm specific 
resistance genes; (5) Stress response to hostile environment conditions i.e. overexpression of 
antimicrobial destroying enzymes. 
Current treatment of PJI involves a two-stage approach. The first stage includes thorough 
debridement of all foreign bodies, infected material and necrotic tissue. It is followed by extensive 
irrigation of the infected site to remove residual debris, biofilm and free floating bacteria. This is 
followed by the implantation of a medium-high dosage antimicrobial-loaded bone cement 
temporary spacer for local antimicrobial delivery. After about 6 weeks to allow for inflammation 
from the first stage to resolve, a second surgical procedure is performed, during which the spacer 
is removed and the joint is reconstructed with a permanent joint prosthesis. The total cost of the 
two-stage revision approach can be five times or more than that of the initial arthroplasty.4,5,25 
Benefits of a one-stage treatment include reduced morbidity, improved functional outcomes, and 
reduced cost.26 However, one-stage treatment is currently not recommended for most patients 
with PJIs in part because there is no opportunity for sustained local antimicrobial delivery in these 
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procedures.27 A new approach capable of providing the necessary antimicrobial concentrations 
locally over a prolonged period of time could enable one-stage treatment if compatible with a 
permanent implant. Our laboratory is developing a sustained-release formulation of antimicrobials 
for local delivery as a part of a one-stage approach to treat PJIs.  
There is a lack of biofilm-related animal models and studies of biofilms grown on tissue and 
material surfaces which reflect the pathogens and tissue and material surfaces involved in PJIs. 
Previously reported evaluation of biofilm susceptibility to antimicrobials has been conducted on in 
vitro grown biofilms on synthetic surfaces.28,29 The information of target antimicrobial 
concentration to prevent the recalcitrance of infection on biological tissues is required. Therefore, 
generating this MBEC data will help establish goals for local drug delivery approaches that can 
improve biofilm associated infection treatment by providing realistic target drug concentrations on 
tissues relevant to PJIs. Therefore, a model of chronic, implant-associated infection of the femur 
in rabbits was developed using bacteria thought to represent common orthopaedic pathogens, 
with the goal of producing infected tissues suitable for MBEC determination ex vivo.  Antimicrobial 
susceptibility studies of bacterial growth on the infected tissues were performed after recovery 
from euthanized animals. Simultaneously biofilms were grown in vitro on aseptically harvested 
tissues and their antimicrobial susceptibilities were studied. The studies involved combinations of 
microorganisms and antimicrobials over exposure durations from 6 hr to 72 hr through 
quantitative microbiological broth dilution assays. 
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CHAPTER 2 – RABBIT IMPLANT INFECTION MODEL  
2.1 Materials and Methods 
2.1.1 Microorganisms and Antimicrobials 
Orthopaedic infections can be caused by a diverse group of bacteria including 50-75% gram-
positives, and 10-20% each gram-negative, polymicrobial, and culture-negative.30-33 Recognizing 
that about 70% of orthopaedic infections are gram-positive staphylococci34-36, a majority of the 
strains we evaluated were staphylococci. The remaining strains represent some of more common 
species seen in non-staphylococcal orthopaedic infections, including Pseudomonas (gram-
negative), Enterococcus, and Streptococcus species. The full list of organisms studied consisted 
of the following: methicillin-resistant Staphylococcus aureus (ATCC BAA 1556 and methicillin 
resistant Staphylococcus aureus (ATCC BAA 1680 – BSL 2), methicillin sensitive Staphylococcus 
aureus (ATCC 49230 – BSL 2), Staphylococcus epidermidis (ATCC 35984 – BSL 1), 
Staphylococcus epidermidis: ATCC (12228 – BSL 1), Streptococcus agalactiae (ATCC 13813 – 
BSL 2), Enterococcus faecalis (ATCC 29212 – BSL 2), and Pseudomonas aeruginosa (ATCC 
27853 – BSL 2). P.aeruginosa ATCC 27853 is gram-negative, while the rest of the pathogens are 
gram-positive.  
Table 2.1 Pathogens and Properties 
 
The antimicrobials tobramycin and vancomycin were chosen as they are the most common drugs 
utilized in local delivery in orthopaedics.37 They are also off-patent, easily available, inexpensive 
Microorganism ATCC# 
S. aureus BAA 1556 
S. aureus BAA 1680 
S. aureus 49230 
S. epidermidis 35984 
S. epidermidis 12228 
S. agalactiae 13813 
E. faecalis 29212 
P. aeruginosa 27853 
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and have minimal local tissue toxicity.38-40 Tobramycin is effective against large number of gram-
negatives and selected gram-positives including staphylcocci,41-43 whereas vancomycin is 
effective against most gram-positive organisms, and resistance to vancomycin is relatively rare.44 
Thus, the two agents together have activity against the vast majority of bacteria found in 
orthopaedic infections, with dual coverage against some of the most common species. 
2.1.2 Animal Model 
 The animal model involved performing inoculation surgery on New Zealand White female 
rabbit in which the inoculum of bacteria was introduced into the femur to cause an infection. In 
addition, foreign materials (stainless steel wire and braided silk suture) simulating foreign bodies 
were also implanted. 
2.1.3 Preparation of Inoculum 
Two days prior to the inoculation surgery, a liquid culture of the microorganism of interest 
was prepared by inoculating a colony of the microorganism from an agar plate using a sterile loop 
into a 20 mL screw cap culture tube (Tube A) containing 3 mL sterile growth medium for the 
microorganism as per the American Type Culture Collection recommendation. 
The tube was sonicated for 30 seconds and incubated overnight at 37°C. The day prior to the 
surgery, the incubated overnight culture was diluted to match the turbidity of a 0.5 McFarland 
standard [1.5x10^8 colony forming units (CFUs)/mL] into a new 20 mL sterile screw cap culture 
tube (Tube B) containing 3 mL sterile growth medium. In addition, a sterile, braided silk suture 
(size 4 measuring ~10 cm in length) was placed in the culture tube and incubated for 24 hours at 
37°C as shown in the figure below.  
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(A)              (B) 
Fig. 2.1 Preparation of biofilm contaminated suture 
(A) Start of incubation containing growth medium and suture (B) After 24 hour incubation with 
suture containing biofilm 
 
Two hours prior to the surgery, the microorganism liquid culture soaked braided suture from Tube 
B was transferred into a sterile 2 mL screw top vial. To this 2 mL screw top vial, 600 µL liquid 
culture was added from Tube B and the vial was closed. 
2.2 Femur Model 
2.2.1  Introduction 
As a part femur infection model, 31 surgeries were performed on 26 rabbits (rabbit 1-24 
and 26-27) among which 5 rabbits (1, 2, 10, 11, and 12) underwent a second inoculation 
procedure as they did not establish an infection after the first. Rabbit 25 was used for a different 
study. Eight rabbits were inoculated with S.aureus (ATCC# 49230), four rabbits were inoculated 
with S.aureus (BAA 1556), three rabbits were inoculated with S.aureus (BAA 1680), four rabbits 
were inoculated with P.aeruginosa (27853), five rabbits were inoculated with S. epidermidis 
(35984), one rabbit each with S.epidermidis (12228), S.agalactiae (13813), and E.faecalis 
(29212). 
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2.2.2  Surgery and Inoculation 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee at St. Joseph's Hospital and Medical Center (Phoenix, AZ). The left hind legs of New 
Zealand White rabbits (Female, ~3 kg) were shaved from the hip to below the knee on the day 
before surgery. Rabbits were operated on under general anesthesia (2-3% isoflurane in oxygen) 
using standard aseptic techniques. 
The lateral portion of one femur of each rabbit was accessed via skin incision, and 3 holes of 2 
mm diameter were drilled through the lateral cortex of the femur. The holes were inoculated with 
approximately with inoculum ranging from 75 µL to 225 µL. Different densities of the inoculum 
were chosen resulting in final count of 1.125x10^7 to 6.75x10^7 colony forming units (CFU). 
Inoculation started with 75 µL and the volume of inoculum was increased in response to failure of 
infections in the animal. A 10-cm long stainless steel Kirschner wire segment was inserted 
through the hole to contact the opposite cortex and protrude slightly from the drill hole. In, 
addition a 10-cm long section of biofilm-containing silk suture was introduced into the wound 
before closing. The silk suture method is expected to be more effective than inoculating with the 
planktonic bacterial suspension alone because it will allow bacteria to form biofilm prior to 
introduction in vivo and protects the bacteria against the host response in the initial stages of 
infection development. 
The surgical site was closed using 4-0 polypropylene suture. The animals were administered 
sustained-release buprenorphine as post-operative analgesia and were monitored to detect 
clinical symptoms of infection (formation of abscess, draining of pus, necrotic tissue) or general 
symptoms that could be indicative of infection (food intake, fatigue, stool and urine output, and 
general behavior). The time for the development infection was generally expected to be 2-2.5 
weeks.     
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Fig. 2.2 Surgical Inoculation Procedure. 
Drilling into the femur prior to irrigation and inoculation with bacterial inoculum soaked (biofilm 
coated) suture, metal k-wire and bacterial inoculum. 
2.2.3 Necropsy and Harvest of Infected Tissues 
 
Fig. 2.3 Recovery of infected tissues from euthanized rabbit (thigh) 
(A) Swelling at the surgery site (B) Recovery of Pus from infection site (C) Necrotic Muscle 
9 
 
Upon observation of apparent infection [Fig. 2.3 (A)], rabbits were sedated with ketamine/xylazine 
and euthanized by pentobarbital injection. A necropsy procedure was then performed to collect all 
foreign bodies and necrotic/infected tissues from the infected site. Using sterile instruments and 
standard aseptic surgical technique including skin preparation with 2% chlorhexidine scrub, the 
infected metal wire, suture, and samples of infected bone, muscle, and pus were recovered and 
stored in labeled, sterilized screw-top tubes for each animal. 
Bone was assumed to be infected based on the presence of pus in the intramedullary canal and 
harvested muscles were recovered based on the presence of visible micro-abscesses or 
plaque/biofilm formation on the tissues. Each vial was sealed tightly with a screw cap and 
transported immediately to ASU for antibiotic susceptibility tests to determine the extent of 
infection quantitatively (MBEC). The antimicrobial exposure was started within four hours after the 
recovery from euthanized animal. 
2.2.4 Results 
Among the 26 rabbits, as shown in the tables (2.2 and 2.3) below, 8 were tested for S. 
aureus (ATCC 49230) with a successful infection in all the cases. 4 rabbits were inoculated with 
S. aureus (ATCC BAA 1556) with a successful infection in 3 cases and the 4th rabbit was 
prematurely euthanized on displaying elevated symptoms of discomfort (loss of appetite, weight 
and increased fatigue). 3 rabbits were inoculated with S. aureus (ATCC BAA 1680) with a 
successful infection in 2 rabbits and the 3rd rabbit was prematurely euthanized due to symptoms 
mentioned previously. 3 rabbits were inoculated with P. aeruginosa (ATCC 27853) with a 
successful infection all 3 cases. Microorganisms that failed to establish an infection were S. 
epidermidis [(ATCC 35984), 5 rabbits], S. epidermidis [(ATCC 12228), 1 rabbit], S. agalactiae 
[(ATCC 13813), 2 rabbits] and E. faecalis [(ATCC 29212), 1 rabbit]. 
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Table 2.2 List of Rabbit Procedures 
Rabbit # Micro Organism ATCC Notes 
1 S. aureus 49230 Infected 2nd inoculation 
2 S. aureus 49230 Infected 2nd inoculation 
3 S. aureus 49230 Infected 1st inoculation 
4 S. aureus 49230 Infected 1st inoculation 
5 S. aureus 49230 Infected 1st inoculation 
6 S. aureus 49230 Infected 1st inoculation 
7 S. aureus 49230 Infected 1st inoculation 
8 S. aureus 49230 Infected 1st inoculation 
9 S. epidermidis 35984 No infection after 1st inoculation 
10 S. epidermidis 35984 No infection after 2nd inoculation 
11 S. epidermidis 35984 No infection after 2nd inoculation 
12 S. epidermidis 35984 No infection after 2nd inoculation 
13 P. aeruginosa 27853 Infected after 1st inoculation 
14 P. aeruginosa 27853 Infected after 1st inoculation 
15 P. aeruginosa 27853 Infected after 1st inoculation 
16 S. epidermidis 35984 No infection after 1st inoculation 
17 S. aureus (MRSA) BAA 1556 Infected after 1st inoculation 
18 S. aureus (MRSA) BAA 1556 Euthanized (no tissues collected) 
19 S. aureus (MRSA) BAA 1556 Infected after 1st inoculation 
20 S. aureus (MRSA) BAA 1556 Infected after 1st inoculation 
21 E.faecalis 29212 No infection after 1st inoculation 
22 S. agalactiae 13813 No infection after 1st inoculation 
23 S. aureus (MRSA) BAA 1680 Infected after 1st inoculation 
24 S. epidermidis 12228 No infection after 1st inoculation 
26 S. aureus (MRSA) BAA 1680 Euthanized (no tissues collected) 
27 S. aureus (MRSA) BAA 1680 Infected after 1st inoculation 
 
Table 2.3 Rabbit surgeries summary (Femur Model) 
Microorganism Result Infection Development 
S. aureus (BAA 1556) 3 of 4 infected + 1 Euthanized 2.5 ~ 3 weeks 
S. aureus (BAA 1680) 2 of 3 infected + 1 Euthanized 1 ~ 1.5 weeks 
S. aureus (49230) 8 of 8 infected 3 ~ 3.5 weeks 
P. aeruginosa (27853) 3 of 3 infected 4 ~ 6 weeks 
S. epidermidis (35984) 0 of 5 infected No infections 
S. epidermidis (12228) 0 of 1 infected No infections 
E. faecalis (29212) 0 of 1 infected No infections 
S. agalactiae (13813) 0 of 1 infected No infections 
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2.2.5 Discussion 
Among the procedures, all 3 strains of Staphylococcus Aureus (ATCC BAA 1556, BAA 
1680 and 49230) resulted in a chronic local infection which supports this experimental procedure 
to be promising for Staphylococcus aureus and Pseudomonas aeruginosa infections. However, 
half of the strains that were inoculated did not result in an infection, including Staphylococcus 
epidermidis, Streptococcus agalactiae and Enterococcus faecalis. 
For cases in which the femoral model failed to result in infection, a second surgery was 
attempted, inoculating a devascularized segment of radius using a model developed by Nelson et 
al.45-47 
2.3 Forelimb Radius Model 
2.3.1  Introduction 
A rabbit model of radial osteomyelitis45-47 has been reported in literature to produce a 
chronic bone infection because it relies on a devascularized segment of bone inside which 
bacteria are isolated from the host response of the rabbit. This is not totally possible in the femur 
site because cutting fully through the femur would lead to instability whereas removal of a large 
portion of the radius does not require fixation and allows the rabbit to ambulate and bear some 
weight on the limb as the ulna remains intact. 
2.3.2 Surgery and Inoculation 
 The radius of the left forelimb was accessed via a skin incision, and a 1.5-2 cm 
diaphyseal segment was removed using a sterile fine-toothed saw. The bone segment was 
inoculated with bacterial suspension approximating the turbidity of a 1.5 McFarland standard and 
placed back in the original site. A biofilm-contaminated suture was also placed in the site along 
with a small stainless steel wire as one of the goals of the study was to cause an implant-related 
infection.  
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Fig. 2.4 Radial infection model (A) Accessing the femur and removing a small section of the rabbit 
ulna to devascularize. (B)Inserting the devascularized bone segment back into the ulna and 
additional inoculum, biofilm coated suture and metal wire.  
2.3.3 Results 
 The table below represents the results of the rabbit radial model inoculations after the 
administration of highest volume possible (150µL, limited due to the space in the bone cavity) 
turbid inoculum of the intended microorganism. 
 
Table 2.4 Rabbit Surgeries Summary (Radial Model) 
Rabbit # Micro Organism ATCC # Notes 
16 S. epidermidis 35984 No infection 
25 S. agalactiae 13813 No infection 
 
2.3.4 Discussion 
 The forelimb radius infection model was adopted after the femur infection model failed to 
establish S.epidermidis (35984), S.agalactiae (13813), E.faecalis (29212), and S.epidermidis 
(12228) infections.  
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In this model, two rabbits were inoculated with S.epidermidis (35984) and S.agalactiae (13813) 
separately with a turbid inoculum containing approximately 225 µL (6.75x10^7 CFU) in addition to 
the biofilm coated suture. Infection failed to establish in both the cases even after a development 
time of 4-5 weeks after the surgical procedure, and the rabbits were euthanized. The 
macroscopic appearance of tissues at the inoculated site showed no evidence of infection upon 
dissection. Tissues from the non-operated limbs were recovered aseptically for separate studies. 
This showed that the radial osteomyelitis model does not apply broadly to all bacteria, including 
some other staphylococci even after the administration of high. In part, based on the lack of 
consistency in rabbit infection outcomes for ex vivo MBEC testing, an alternative experiment was 
planned to grow biofilm on biological tissue specimens in vitro where the growth is uninhibited 
due to the absence of the host response of an animal. Although this would result in a biofilm that 
may not perfectly mimic in vivo biofilm given the uninhibited growth, we hypothesized that the 
MBEC values obtained would be no greater than the antimicrobial concentrations necessary to 
eradicate biofilms established in vivo on comparable surfaces.  
14 
 
CHAPTER 3: EX VIVO TISSUE MINIMUM BIOFILM ERADICATION CONCENTRATION (MBEC) 
AND MINIMUM INHIBITORY CONCENTRATION (MIC) 
3.1 Ex vivo Tissue Minimum Biofilm Eradication Concentration (MBEC) 
3.1.1 Materials and Methods 
Infected, freshly recovered samples of bone, muscle, pus, implant and suture obtained 
from necropsy (2.1.5) were aseptically divided into smaller specimens (40 mg each) and 
individually placed into the wells of a 96 well plate. MBEC was measured for all possible 
permutations that were limited by the recovered infected tissues. Four microorganisms (ATCC # 
BAA 1556, BAA 1680, 49230, 27853) resulted in established infections. Five specimen types and 
3 drug combinations over 3 exposure durations were measured for S. aureus (BAA 1556), S. 
aureus (49230) and P. aeruginosa (27853). For the microorganism S. aureus (BAA 1680), the 
recovered tissue specimens were limited to one rabbit. Tissues from a single rabbit yielded 
enough specimens to evaluate MBEC for a single antimicrobial combination for all 5 materials at 
all 3 exposure times. Therefore, only one drug combination (TOB) was tested for 5 specimen 
types over 3 exposure durations for BAA-1680. Plated specimens were exposed to 200 µL 
antimicrobial media [antimicrobial agent(s) in tryptic soy broth (TSB)] ranging from 4000 µg/mL to 
31 µg/mL (4000, 2000, 1000, 750, 500, 375, 250, 125, 62, 31 in µg/ml) of three drug 
combinations (TOB, VANC, TOB+VANC) over three exposure durations (6 h, 24 h and 72 h). 
TOB+VANC denotes equal amounts of tobramycin and vancomycin, where 1000 µg/ml 
TOB+VANC consists of 500 µg/ml of each agent. The inclusion of 750 and 375 µg/mL was done 
to accommodate more concentration levels to be tested in our range of interest which is 
consistent with the general local antimicrobial delivery levels (100 – 1000 µg/mL) achieved by an 
investigational formulation being developed in our lab and reported in literature for other high-
dose formulations.45 After the exposure duration, the specimens were rinsed 4 times with 200 µL 
of sterile medium to remove residual antimicrobial. Each rinsed sample was subcultured in 
separate screw top culture tubes with 3 mL TSB at 37°C to observe the microbial growth over a 
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period of 3 weeks. The lowest concentration at which there was no visible growth of the 
microorganism in the subculture tube was determined to be the minimum biofilm eradication 
concentration.  
Subculture tubes were classified as positive (turbid) or negative (transparent) based on visible 
inspection at up to 21 days following subculture. MBEC was generally interpreted as the lowest 
concentration at which a negative subculture was obtained. Single negative subcultures between 
multiple positive subcultures were interpreted as false negative and the negative subculture at the 
next highest concentration was selected as the MBEC value. Also, a positive subculture was 
interpreted as a false negative if it was seen with multiple negative values at lower 
concentrations. Additionally, if there were multiple gaps (inconsistent positive and negative 
subcultures), the MBEC values was marked as undetermined. 
The figure below represents a typical antimicrobial exposure plate where the tissue specimens 
were divided into small pieces to fit into the 96 well plate. They were exposed to antimicrobials of 
different drug combinations (TOB, VANC and TOB+VANC) over three distinct exposure durations 
(6 hour, 24 hour, 72 hour). 
 
 
 Fig. 3.1 MBEC plate setup for ex vivo tissue antimicrobial exposure 
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The figure below represents the subculture analysis where the specimens exposed to 
antimicrobials were subcultured. The numbers in white represent the antimicrobial concentration 
to which the specimens were exposed. In this particular case, the MBEC was determined to be 
500 µg/mL after interpreting it to not show any microbial growth evident by the non turbid growth 
medium. 
 
 Fig. 3.2 Results after subculture, all concentrations in µg/mL; values shown in white 
correspond to the antimicrobial concentration (µg/mL) to which the specimens were exposed prior 
to subculture. The MBEC for this series of samples was determined to be 500 µg/mL.  
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3.1.2 Results  
Table 3.1 Raw data table of ex vivo MBEC representing the microorganism S. aureus (BAA 1556) 
vs VANC 
6 h exposure 
Antibiotic Concentration in µg/mL 
 
4000 2000 1000 750 500 375 250 125 62 31 control MBEC 
Bone - - - - - - + + + + + 375 
Muscle - + - - - - - + + + + 250 
Pus - - - + + + + + + + + 1000 
Implant + + + + + + + + + + + >4000 
Suture - - - + + + + + + + + 1000 
    
  
24 h exposure 
Antibiotic Concentration in µg/mL 
 
4000 2000 1000 750 500 375 250 125 62 31 control MBEC 
Bone - - + - + - + + + + + undetermined 
Muscle - - - - - - - + + + + 250 
Pus - - - - + + + + + + + 750 
Implant - - + - - + + + + + + 500 
Suture - - - - + - + + + + + 750 
      
  
72 h exposure 
Antibiotic Concentration in µg/mL 
 
4000 2000 1000 750 500 375 250 125 62 31 control MBEC 
Bone - - - - + - - + - + + undetermined 
Muscle - - - + - - - + + - + undetermined 
Pus + - - - - + + + + + + 500 
Implant - - - - - - + - - - + 31 
Suture - - - + - - + - + + + undetermined 
There were undetermined values (24 hour exposure of antimicrobial to implant specimen, 
muscle sample at 72 hour exposure and suture sample at 72 hour exposure) where false 
negatives and positives were observed and hence were not able to determine the actual MBEC. 
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Table 3.2 Ex vivo MBEC of S. aureus (BAA 1556) 
  TOB VANC TOB+VANC 
 Material 6 h 24 h 72 h 6 h 24 h 72 h 6 h 24 h 72 h 
Bone 2000 125 750 375 n/a n/a 2000 500 125 
Muscle 2000 250 375 250 250 n/a 250 375 125 
Pus >4000 >4000 >4000 1000 750 500 375 125 31 
Implant 31 31 31 >4000 500 31 31 31 31 
Suture 1000 750 1000 1000 750 375 125 31 31 
*n/a – values undetermined due to multiple gaps 
Table 3.3 Ex vivo MBEC of S. aureus (BAA 1680) 
  TOB 
Material  6 Hr 1 Day 3 Day 
Bone 250 1000 125 
Muscle 4000 375 750 
Pus >4000 2000 1000 
Implant 250 31 31 
Suture 31 31 31 
 
Table 3.4 Ex vivo MBEC of S. aureus (49230) 
  TOB VANC TOB+VANC 
  6 h 24 h 72 h 6 h 24 h 72 h 6 h 24 h 72 h 
Bone 31 31 125 >4000 4000 >4000 >4000 1000 31 
Muscle 2000 375 375 2000 1000 n/a 4000 750 125 
Pus 2000 2000 125 ns 4000 ns 1000 >4000 2000 
Implant 31 31 31 >4000 n/a 31 31 31 31 
Suture 375 31 125 4000 2000 n/a >4000 250 250 
n/a – undetermined due to inconsistency 
ns – no sample obtained from the euthanized, infected rabbit. 
Table 3.5 Ex vivo MBEC of P. aeruginosa (27853) 
  TOB VANC TOB+VANC 
  6 h 24 h 72 h 6 h 24 h 72 h 6 h 24 h 72 h 
Bone 4000 125 125 4000 >4000 >4000 >4000 4000 1000 
Muscle >4000 750 375 >4000 >4000 >4000 4000 4000 4000 
Pus ns 4000 ns ns >4000 ns >4000 >4000 >4000 
Implant 31 31 31 500 125 125 31 31 31 
Suture >4000 >4000 2000 >4000 >4000 750 >4000 4000 125 
ns – no sample was obtained from the euthanized, infected rabbit. Due to pus being runny and 
the consistent specimen of pus being a smaller sample, it was tested only for 24 hour 
exposure times. 
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Table 3.6 Ex vivo Tissue MBEC in bone and muscle 
Bone 
ATCC# 
Exposure 
Time MBEC 
    TOB VANC TOB+VANC 
BAA 1556 
6 h 2000  375  2000  
24 h  125  2000  500 
72 h  750 undetermined  125 
BAA 1680 
6 h  250 no data  no data  
24 h  1000 no data  no data  
72 h  125 no data  no data  
49230 
6 h undetermined  >4000 >4000  
24 h 31  4000  1000 
72 h 125  >4000  31 
27853 
6 h  4000  >4000  >4000 
24 h  undetermined  >4000  4000 
72 h  125  >4000  1000 
 
Muscle 
ATCC# 
Exposure 
Time MBEC 
    TOB VANC TOB+VANC 
BAA 1556 
6 h 2000  250  250 
24 h 250  250  375 
72 h 375  250  125 
BAA 1680 
6 h  4000 no data  no data  
24 h  375 no data  no data  
72 h  750 no data  no data  
49230 
6 h 2000 2000  375  
24 h 375  1000  750 
72 h 375  2000  undetermined 
27853 
6 h  >4000 >4000   4000 
24 h  4000  >4000  4000 
72 h  375  >4000  4000 
 
3.1.3 Discussion 
Although the experimental approach pursued in this study generally allowed for determination of 
MBEC on tissue and biomaterial surfaces infected in vivo, the method has a number of 
weaknesses. First, 50% of the microorganisms that were inoculated failed to cause an infection. 
Second, the raw data were difficult to interpret due to inconsistency in subculture results leading 
to many undetermined MBEC values. Third, the ones that infected successfully, produced 
inconsistent data due to a majority of MBEC values obtained did not decrease with time which in 
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contrast to the research showing the increase in susceptibility of biofilm to antimicrobials with 
increase in exposure time.48  
3.2 Minimum Inhibitory Concentration (MIC) 
 Minimum inhibitory concentration (MIC) can be defined as the lowest antimicrobial agent 
concentration preventing the visible growth of microorganisms after an overnight incubation. A 
low MIC value indicates high sensitivity of the microorganism towards corresponding antimicrobial 
agent.  
3.2.1 Materials and Methods 
Minimum inhibitory concentration was measured by the CLSI standard broth microdilution 
method49 and median MIC (antimicrobial concentration required to inhibit the growth of at least 
50% of the tested strains) and MICmax (antimicrobial concentration required to kill all the tested 
strains) was used in comparing the spectrum of activity of the antimicrobial combinations. 
For a given study, the microorganism of interest was grown overnight in cation-adjusted Mueller-
Hinton Broth (Sigma-Aldrich 90922), and the concentration was adjusted to approximately 
1.5x10^6 CFU using the same media. Bacteria were exposed to three antimicrobial combinations 
(100% Tobramycin, 100% Vancomycin and 1:1 combination of each) at each of ten total 
antimicrobial concentrations (128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25 µg/mL) and one negative 
control in sterile round bottomed 96 well tissue culture plate (Biofil TCP 002096) before 
incubation for 18-20 hours at 37°C. The lowest antimicrobial concentration at which there was no 
visible growth of the microorganism was considered the MIC. 
Table 3.7 MIC of S. aureus (49230) 
  Concentration of Antimicrobial Combination (µg/ml) 
  128 64 32 16 8 4 2 1 0.5 0.25 Control MIC 
TOB - - - - - - - - + + + 1 
VANC - - - - - + + + + + + 8 
TOB+VANC - - - - - - - + + + + 2 
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3.2.2 Results 
 The data interpretation shows the single agents TOB and VANC had MIC ≤ 8 µg/mL against 6 
out of 8 tested microorganisms and the antimicrobial combination of TOB+VANC had MIC ≤ 8 
µg/mL against all the tested 8 microorganisms. On a closer observation with median MIC as a 
standard, TOB measured as 2 µg/mL and VANC measured 4 µg/mL as well whereas the 
antimicrobial combination measured as 4 µg/mL 
Table 3.8 Minimum Inhibitory Concentration Results 
ATCC # MIC TOB 
(µg/mL) 
MIC VANC 
(µg/mL) 
MIC TOB+VANC 
(µg/mL) 
S.aureus (BAA 1556) 2 4 1 
S.aureus (BAA 1680) 2 2 2 
S.aureus (49230) 1 8 2 
S.epidermidis (35984) 128 2 4 
P.aeruginosa (27853) 8 >128 8 
E.faecalis (29212) 64 2 4 
E.coli (25922) 2 >128 8 
Median MIC 2 4 4 
MICmax 128 >128 8 
 
3.2.3 Discussion 
 For the tested microorganisms, the use of combination of antimicrobial agent combination 
(TOB+VANC) showed a wider coverage over microorganisms, which can be shown by its MICmax 
value that was 8 µg/mL. In comparison, for treatments with TOB it was 128 µg/mL and VANC it 
was greater than 128. Also, the median MIC value (inhibiting the growth of at least half of the 
tested strains) for the antimicrobial treatment TOB+VANC was comparable to both the single 
agents (TOB or VANC). 
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CHAPTER 4: IN VITRO TISSUE MINIMUM BIOFILM ERADICATION CONCENTATION 
4.1 Materials and Methods 
From the previous chapter, studies resulted in incomplete and inconsistent data. 
Therefore, a different approach was adopted to grow the biofilms on animal tissues in vitro and 
estimate the MBEC values. It was expected that the data generated would be more consistent as 
the variability of infection found in different animals or within animals would be reduced and that 
MBEC values could be determined for all biofilm-forming bacteria. 
4.1.1 Materials 
Tissues (bone and muscle) were obtained from healthy uninoculated limbs aseptically 
harvested from euthanized female New Zealand White rabbits used in the rabbit implant infection 
model (Section 2.1.5). Specimens of bone were obtained from femora and the muscle samples 
were obtained from the adjacent muscles. 
4.1.2 Methods 
Eight microorganisms were chosen for this study which included S. aureus (BAA 1556), 
S. aureus (BAA 1680), S. aureus (49230), S. epidermidis (35984), S. epidermidis (12228), E. 
Faecalis (29212), P. aeruginosa (27853) and E. coli (25922). P. aeruginosa and E. coli are gram-
negative and the other bacteria used are gram-positive. 
Tissues were divided into specimens of approximately 40 mg each and plated in sterile 96 well 
tissue culture plate (Celltreat 229197). To the specimens, 200 µL bacterial inoculum (grown 
overnight at 37°C and diluted 1:30 in TSB with 1% glucose) was added and incubated for 72 
hours at 37°C to allow for biofilm growth on the tissues. After incubation, the biofilm-contaminated 
tissue specimens were transferred into a new sterile 96 well plate. Specimens were exposed to 
200 µL antimicrobial combinations (antimicrobial in TSB) ranging from 4000 µg/mL to 31 µg/mL 
(4000, 2000, 1000, 750, 500, 375, 250, 125, 62, 31 in µg/ml) to three drug combinations 
(tobramycin, vancomycin, 1:1 weight combination of both tobramycin and vancomycin), three 
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distinct exposure durations (6 hr, 24 hr and 72 hr) and subsequently rinsed to remove residual 
antimicrobials. Each rinsed sample was subcultured in separate screw-top culture tubes with 3 
mL TSB at 37°C to observe microbial growth over a period of 3 weeks. The subculture tube 
representing the specimen exposed to the lowest concentration at which there was no visible 
growth of the microorganism was determined as the in vitro MBEC. 
 
Fig. 4.1 MBEC plate setup for in vitro tissue antimicrobial exposure 
Subculture tubes were classified as positive (turbid) or negative (transparent) based on visible 
inspection at up to 21 days following subculture. MBEC was generally interpreted as the lowest 
concentration at which a negative subculture was obtained. Single negative subcultures between 
multiple positive subcultures were interpreted as false negative and the negative subculture at the 
next highest concentration was selected as the MBEC value. Also, a positive subculture was 
interpreted as a false negative if it was seen with multiple negative values at lower 
concentrations. Additionally, if there were multiple gaps (inconsistent positive and negative 
subcultures), the MBEC values was marked as undetermined. 
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 Table 4.1 Example of a Raw data table of in vitro tissue MBEC representing the microorganism 
S. aureus (49230) vs TOB+VANC 
6 h exposure 
Antibiotic Concentration in µg/ml 
 
4000 2000 1000 750 500 375 250 125 62 31 control MBEC 
Bone - - - - + + - + + + + 750 
Muscle - - - - - - + + + + + 375 
Implant + - - + - + + - + + + undetermined 
 24 h exposure 
Antibiotic Concentration in µg/ml 
 
4000 2000 1000 750 500 375 250 125 62 31 control MBEC 
Bone - - - + + + + + + + + 1000 
Muscle - - - - - + + + + + + 500 
Implant - - - - - - - - + - + 125 
 72 h exposure 
Antibiotic Concentration in µg/ml 
 
4000 2000 1000 750 500 375 250 125 62 31 control MBEC 
Bone - - - - - + + + + + + 500 
Muscle - - - - - + + + + + + 500 
Implant + - - - - - - - - - + 31 
 
 
 
Fig. 4.2 In vitro tissue MBEC representing S. aureus (49230) vs TOB+VANC 
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4.2 Results 
Samples were sent to Antech Diagnostics and culture analysis and were confirmed that 
biofilms grown on tissues were of the intended organism. 
Table 4.2 In vitro tissue MBEC of S. aureus (BAA 1556) 
 
TOB (µg/mL) VANC (µg/mL) TOB+VANC (µg/mL) 
 
Bone S.Tissue Implant Bone S.Tissue Implant Bone S.Tissue Implant 
6 h 500 2000 4000 >4000 4000 >4000 >4000 4000 - 
24 h 2000 375 >4000 >4000 2000 >4000 4000 125 250 
72 h 250 250 >4000 >4000 1000 >4000 750 125* 62 
 * - Possible synergy 
  
 
Table 4.3 In vitro tissue MBEC of S. aureus (BAA 1680) 
 
TOB (µg/mL) VANC (µg/mL) TOB+VANC (µg/mL) 
 
Bone S.Tissue Implant Bone S.Tissue Implant Bone S.Tissue Implant 
6 h >4000 >4000 4000 >4000 4000 >4000 4000 750* 1000 
24 h >4000 >4000 31 >4000 2000 >4000 >4000 250* - 
72 h >4000 4000 - >4000 2000 >4000 4000 250* - 
 * - Possible synergy 
 ** - value could not be determined due to inconsistencies in sub culture data 
 
Table 4.4 In vitro tissue MBEC of S. aureus (49230) 
 
TOB (µg/mL) VANC (µg/mL) TOB+VANC (µg/mL) 
 
Bone S.Tissue Implant Bone S.Tissue Implant Bone S.Tissue Implant 
6 h 4000 500 >4000 >4000 2000 >4000 750 375 -** 
24 h 500 375 - >4000 >4000 >4000 1000 500 125 
72 h 125 250 750 4000 1000 >4000 500 500 31 
** – value could not be determined due to inconsistencies in sub culture data 
 
Table 4.5 In vitro tissue MBEC of S. epidermidis (35984) 
 
TOB (µg/mL) VANC (µg/mL) TOB+VANC (µg/mL) 
 
Bone S.Tissue Implant Bone S.Tissue Implant Bone S.Tissue Implant 
6 h >4000 >4000 >4000 >4000 4000 >4000 >4000 750 31 
24 h >4000 >4000 >4000 4000 750 >4000 >4000 2000 -** 
72 h >4000 >4000 >4000 2000 375 >4000 4000 750 31 
 ** - value could not be determined due to inconsistencies in sub culture data 
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Table 4.6 In vitro tissue MBEC of E. faecalis (29212) 
 
TOB (µg/mL) VANC (µg/mL) TOB+VANC (µg/mL) 
 
Bone S.Tissue Implant Bone S.Tissue Implant Bone S.Tissue Implant 
6 h >4000 >4000 31 2000 250 >4000 >4000 2000 4000 
24 h >4000 >4000 -** 1000 250 -** >4000 500 >4000 
72 h >4000 >4000 -** 1000 750 >4000 4000 250 1000 
  
 
Table 4.7 In vitro tissue MBEC of P. aeruginosa (27853) 
 
TOB (µg/mL) VANC (µg/mL) TOB+VANC (µg/mL) 
 
Bone S.Tissue Implant Bone S.Tissue Implant Bone S.Tissue Implant 
6 h >4000 2000 31 >4000 >4000 375 750 750 500 
24 h >4000 375 31 >4000 >4000 250 125 750 250 
72 h 4000 62 31 >4000 >4000 125 125 375 375 
 
 
Table 4.8 In vitro tissue MBEC of E. coli (25922) 
  TOB (µg/mL) VANC (µg/mL) TOB+VANC (µg/mL) 
  Bone S.Tissue 
Implan
t Bone S.Tissue Implant Bone S.Tissue 
Impla
nt 
6 h >4000 125 31 >4000 >4000 250 >4000 4000 31 
24 h 4000 375 125 >4000 >4000 375 >4000 4000 31 
72 h 4000 125 31 >4000 4000 250 -** 2000 31 
 ** - value could not be determined due to inconsistencies in sub culture data 
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The table below represents the summary of in vitro bone MBEC. The values highlighted in red 
indicate high MBEC values and the values in blue text indicate MBEC values obtained using 
cancellous bone. 
Table 4.9 Summary of Bone in vitro MBEC 
Micro organism Exposure time MBEC 
  
TOB VANC TOB+VANC 
S.aureus BAA 1556 
6 h >4000 >4000 >4000 
24 h 2000 >4000 4000 
72 h 250 >4000 750 
S.aureus BAA 1680 
6 h >4000 >4000 4000 
24 h >4000 >4000 >4000 
72 h 4000 >4000 4000 
S.aureus (49230) 
6 h 4000 >4000 750 
24 h 500 >4000 1000 
72 h 125 4000 500 
S.epidermidis (35984) 
6 h >4000 >4000 >4000 
24 h >4000 4000 >4000 
72 h >4000 2000 4000 
E.faecalis (29212) 
6 h >4000 2000 >4000 
24 h >4000 1000 >4000 
72 h >4000 1000 4000 
P.aeruginosa (27853) 
6 h >4000 >4000 750 
24 h >4000 >4000 125 
72 h 4000 >4000 125 
E.coli (25922) 
6 h >4000 >4000 >4000 
24 h 4000 >4000 >4000 
72 h 4000 >4000 undetermined 
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The table below represents the summary of in vitro muscle MBEC. The values highlighted in red 
indicate high MBEC values. 
Table 4.10 Summary of Muscle in vitro MBEC 
Micro organism Exposure time MBEC 
  TOB VANC TOB+VANC 
S.aureus BAA 1556 
6 h 2000 4000 500* 
24 h 375 2000 125* 
72 h 250 1000 125* 
S.aureus BAA 1680 
6 h >4000 4000 750* 
24 h >4000 2000 250* 
72 h 4000 2000 250* 
S.aureus (49230) 
6 h 500 >4000 375 
24 h 375 >4000 500 
72 h 250 2000 500 
S.epidermidis 
(35984) 
6 h >4000 4000 750* 
24 h >4000 750 2000 
72 h >4000 375 750 
E.faecalis (29212) 
6 h >4000 250 2000 
24 h >4000 250 500 
72 h >4000 750 250* 
P.aeruginosa 
(27853) 
6 h 2000 >4000 750 
24 h 375 >4000 750 
72 h 62 >4000 375 
E.coli (25922) 
6 h 125 >4000 4000^ 
24 h 375 >4000 4000^ 
72 h 125 4000 2000^ 
 * - Possible Synergy 
 ^ - Possible Antagonism 
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The below table represents the in vitro MBEC values of the implant samples. The majority of 
values were either undetermined or did not fall within the measured range (31 - 4000µg/mL). 
Data were not analyzed further. 
Table 4.11 Summary of Implant in vitro MBEC 
Micro organism exposure time MBEC 
  
TOB VANC TOB+VANC 
S.aureus BAA 1556 
6 h 4000 >4000 undetermined 
24 h >4000 >4000 250 
72 h >4000 >4000 62 
S.aureus BAA 1680 
6 h 4000 >4000 1000 
24 h 31 >4000 undetermined 
72 h undetermined >4000 undetermined 
S.aureus (49230) 
6 h >4000 >4000 undetermined 
24 h undetermined >4000 125 
72 h 750 >4000 31 
S.epidermidis 
(35984) 
6 h >4000 >4000 31 
24 h >4000 >4000 undetermined 
72 h >4000 >4000 31 
E.faecalis (29212) 
6 h 31 >4000 4000 
24 h undetermined undetermined >4000 
72 h undetermined >4000 1000 
P.aeruginosa 
(27853) 
6 h 31 375 500 
24 h 31 250 250 
72 h 31 125 375 
E.coli (25922) 
6 h 31 250 31 
24 h 125 375 31 
72 h 31 250 31 
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4.2.1 Comparison of in vitro tissue median MBECs of Bone and Muscles 
 
Table 4.10 Median of in vitro Bone MBEC for tested 7 microorganisms 
Table 4.12 Median of in vitro Bone MBEC for tested 7 microorganisms 
 
6 h 24 h 72 h 
TOB >4000 >4000 4000 
VANC >4000 >4000 >4000 
TOB+VANC >4000 >4000 4000 
 
Overall, the vast majority of the bone MBEC values were high and did not fall into the range of 
concentrations evaluated in this study (31 – 4000 µg/mL) as seen in the figure below. Given the 
low ratio of MBEC values determined in the bone, an analysis would not account for an unbiased 
one and therefore, it was not included further.  
 
Fig. 4.3 Median for in vitro Bone MBEC 
Table 4.13 Median of in vitro Muscle MBEC for tested 7 microorganisms 
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Fig. 4.4 Median for in vitro Muscle MBEC 
Median values indicate the concentration of antimicrobial concentrations required to kill at least 
fifty percent of the tested microorganism strains (4 out of 7). The table indicates an increase of 
susceptibility with increase in exposure duration to the antimicrobials. 
 
Table 4.14 In Vitro Muscle MBEC of Microorganisms at 6 hour 
ATCC # MBEC TOB 
(µg/mL) 
MBEC VANC 
(µg/mL) 
MBEC TOB+VANC 
(µg/mL) 
S.aureus (BAA 1556) 2000 4000 500* 
S.aureus (BAA 1680) >4000 4000 750* 
S.aureus (49230) 500 >4000 375 
S.epidermidis (35984) >4000 4000 750 
P.aeruginosa (27853) 2000 >4000 750 
E.faecalis (29212) >4000 250 2000 
E.coli (25922) 125 >4000 4000^ 
Median 2000 4000 750 
MBECmax >4000 >4000 4000 
 * - Possible Synergy 
 ^ - Possible Antagonism 
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Table 4.15 In Vitro Muscle MBEC of Microorganisms at 24 hour 
ATCC # MBEC TOB 
(µg/mL) 
MBEC VANC 
(µg/mL) 
MBEC TOB+VANC (µg/mL) 
S.aureus (BAA 1556) 375 2000 125* 
S.aureus (BAA 1680) >4000 2000 250* 
S.aureus (49230) 375 >4000 500 
S.epidermidis (35984) >4000 750 2000 
P.aeruginosa (27853) 375 >4000 750 
E.faecalis (29212) >4000 250 500 
E.coli (25922) 375 >4000 4000^ 
Median 375 2000 500 
MBECmax >4000 >4000 4000 
* - Possible Synergy 
 ^ - Possible Antagonism 
 
Table 4.16 In Vitro Muscle MBEC of Microorganisms at 72 hour 
ATCC # MBEC TOB 
(µg/mL) 
MBEC VANC 
(µg/mL) 
MBEC TOB+VANC 
(µg/mL) 
S.aureus (BAA 1556) 250 1000 125* 
S.aureus (BAA 1680) 4000 2000 250* 
S.aureus (49230) 250 2000 500 
S.epidermidis (35984) >4000 375 750 
P.aeruginosa (27853) 62 >4000 375 
E.faecalis (29212) >4000 750 250 
E.coli (25922) 125 4000 2000** 
Median 250 2000 375 
MBECmax >4000 >4000 2000 
 * - Possible Synergy 
 ** - Possible Antagonism 
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Fig. 4.5 In vitro muscle median and maximum MBEC 
Analyzing the median in vitro muscle MBEC values, the antimicrobial combination TOB+VANC is 
either comparable to or lower than that of the single agents alone. The MBECmax shows all 7 
microorganisms’ biofilms are susceptible to TOB+VANC in the tested range which is not the case 
for the single agents alone.  
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4.3 Discussion 
 Biofilms were successfully established on animal tissues in vitro as expected for seven 
out of the eight organisms. The microorganism S. agalactiae (13813) did not form biofilms which 
was inferred from negative subculture results of the positive control. 
The data from this study was more internally consistent as compared to the ex vivo tissue MBEC. 
The subculture data allowed for straightforward interpretation of the MBEC with fewer “gaps” due 
to false positive or false negative results, indicating less variability between individual samples. 
This method also requires reduced use of animals and affords more flexibility in experimental 
timing.  Overall, most MBEC values measured using cortical bone exceeded 4000 µg/mL, which 
was the maximum concentration evaluated in this study. However, most of the MBEC values for 
muscle samples were in the tested range and showed increased susceptibility with antimicrobial 
exposure duration in most cases. A possible explanation for the extremely high MBECs observed 
in bone is that the bacteria were able to grow throughout the bone and the transport of the 
antimicrobials was limited, either due to the physical dense structure of the bone or its chemical 
interactions with the antimicrobials. This suggests that local delivery of antimicrobials may not be 
effective at any level against infection in intact cortical bone, placing high priority on thorough 
surgical debridement. 
Because the antimicrobial combination TOB+VANC covers a broader spectrum (all the tested 
microorganisms are sensitive to TOB+VANC) of microorganisms and its action of susceptibility 
being comparable to that of TOB alone, a dual agent strategy appears superior in formulations for 
local delivery. 
For the duration of antibiotic exposure, the MBEC values at 24 hour exposure are lower than 6 
hour exposure and comparable to 72 hour exposure. 
  
35 
 
4.4   Comparison of MIC against MBEC of muscle at 24 hour antimicrobial exposure 
 
Table 4.17 MIC of Microorganisms 
ATCC # MIC TOB 
(µg/mL) 
MIC VANC (µg/mL) MIC TOB+VANC 
(µg/mL) 
S.aureus (BAA 1556) 2 4 1 
S.aureus (BAA 1680) 2 2 2 
S.aureus (49230) 1 8 2 
S.epidermidis (35984) 128 2 4 
P.aeruginosa (27853) 8 >128 8 
E.faecalis (29212) 64 2 4 
E.coli (25922) 2 >128 8 
Median 2 4 4 
MICmax 128 >128 8 
 
 
Table 4.18 In vitro MBEC of Muscle 
  
TOB (µg/mL) 
VANC 
(µg/mL) 
TOB+VANC 
(µg/mL) 
6 hour 
Median 2000 4000 750 
MBECmax >4000 >4000 4000 
24 hour 
Median 375 2000 500 
MBECmax >4000 >4000 4000 
72 hour 
Median 250 2000 375 
MBECmax >4000 >4000 2000 
 
Compared against MIC (Table 4.12), the MBEC values (Table 4.11) generally lie between 
100 – 1000x higher as seen in the tables above. This allows for an interpretation that 
delivering an antimicrobial agent locally at the infected site, even if sufficient to kill planktonic 
bacteria, it is not sufficient to eradicate bacteria in biofilm.  
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4.5 Correlation between MIC and in vitro tissue MBEC 
The below figure represents a plot correlating the logarithmic (base 2) values of MIC and 
corresponding in vitro muscle MBEC at 24 hour antimicrobial exposure for the same 
microorganism and same antimicrobial treatment. 
 
Fig. 4.6 Correlation plot of log2(MIC) vs log2(in vitro MBEC) 
The R-squared value of 0.48 shows a weak but a possible correlation between MIC and MBEC 
data when pooled across all strains tested. With more careful analysis limited within specific 
species of organisms, the correlation between MIC and MBEC could improve and possibly 
support the use of MIC to estimate relative MBEC values of different antimicrobial treatments or 
exposure times.  
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CHAPTER 5: CONCLUSIONS 
5.1  Rabbit implant infection model  
This research document reports on the experimental approach in developing an in vivo 
rabbit biofilm related bone infection model on biological tissues and to measure the ex vivo 
minimum biofilm eradication concentration on those tissues. A chronic infection was established 
using four out of eight microorganisms tested. The microorganisms that successfully caused the 
infection were three S.aureus species (ATCC strains BAA 1556, BAA 1680 and 49230) and P. 
aeruginosa (ATCC 27853) and the tissues obtained from these animals were tested for MBEC. 
Infection did not establish using one biofilm forming S. epidermidis (ATCC 35984) and one non-
biofilm forming S. epidermidis strain (ATCC 12228), S. agalactiae (ATCC 13813) and E. Faecalis 
(ATCC 29212). A second surgery was performed and the rabbits were reinoculated for 
S.epidermidis (35984) and S. agalactiae (13813). A different approach with the rabbit radius 
(Nelson et al.) was adopted after the failure of infection establishment which also failed to 
establish infection for S. epidermidis (35984) and S. agalactiae (13813). 
5.2 Ex vivo tissue minimum biofilm eradication concentration (MBEC) and Minimum inhibitory 
concentration (MIC) 
The project measured the ex vivo tissue MBEC values for the tissues obtained from 
infected rabbits. Analysis showed anomalies and inconsistencies that did not result in the 
determination of the actual MBEC values. Since the data was inadequate to establish a definite 
conclusion, a newer approach had to be adopted to measure the MBEC by growing biofilms on 
biological tissues in laboratory conditions. This allowed us to grow the biofilms on biological 
tissues without the presence of host immunity response thereby expecting a more consistent 
biofilm infected tissues and a larger data generated in a shorter duration. 
MIC tests were performed to assess the susceptibility of the microorganisms of interest against 
three antimicrobial combinations (TOB, VANC, TOB+VANC). MIC75 values for TOB+VANC were 
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lower than the single agents (TOB or VANC) and TOB+VANC had a wider coverage given 
findings show only 6 out of 8 microorganisms were sensitive to either TOB or VANC, but all the 8 
microorganisms were sensitive to the combination TOB+VANC. 
5.3 In vitro tissue minimum biofilm eradication concentration (MBEC) 
 As anticipated, biofilms were successfully grown in vitro on the biological surfaces. Broth 
dilution antimicrobial susceptibility tests were performed on tissues after growing biofilms. MBEC 
obtained were significant, consistent and antimicrobial susceptibility increased with time. The 
bone MBEC values were too high and similar for statistical analysis. 
Statistical studies of muscle MBEC values showed TOB+VANC to be the superior option among 
the three antimicrobial combinations for treatment with its median MBEC being comparable to the 
best treatment (TOB) and MBECmax eradicating all eight microorganisms in contrast to only 6 out 
of 8 for the antimicrobial combinations as single agents (TOB or VANC) alone.  
Analyzing the antimicrobial exposure durations, 24 hour exposure showed optimum results with 
the 24 hour exposure time resulted in lower MBEC compared to 6 hour exposure and similar 
MBEC compared to 72 hour exposure.  
A comparison was made between the MIC of microorganisms and corresponding MBEC values 
of muscle at 24 hour exposure for all 3 antimicrobial combinations. On an average the MBEC 
values were 100 – 1000x higher than the MIC values proving MIC level antimicrobial delivery at 
infection sites would not eliminate the biofilm bacteria. An additional observation showed a 
possible correlation between MIC and MBEC showing MIC to be a possible metric to determine 
the relative susceptibility of biofilm bacteria to various antimicrobial treatments. 
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